biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > recent press and videos

<< Previous

Bullboard Posts

Next >>

Comment by Finallytherockon Jul 09, 2021 1:20pm

152 Views

Post# 33521802

RE:recent press and videos

Much appreciate that you provided this post showing the recent news releases. I think it helps that they get the word out on multiple outlets. Clearly, judging by the volume, very few people know about this company. I was disappointed the recent news didn't get us moving. I know the data is still very early and they did not provide much detail but still. We need to hear from Chiasi and Prothena. The company needs to give us more guidance on these programs. I am hoping at the next shareholder meeting or earnings call, the ceo will be pressed on these things

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing